☆ 4.7 Editorial Material

PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy

CLINICAL CANCER RESEARCH (2022)

Related references

Note: Only part of the references are listed.
Article Oncology

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

Janet K. Peper-Gabriel et al.

Summary: This study generated a PD-L1/4-1BB bispecific molecule, PRS-344/S095012, that combines checkpoint blockade with 4-1BB stimulation, increasing antitumor immunity and demonstrating strong antitumoral efficacy in a mouse model.

CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Oncology

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik et al.

Summary: GEN1046 is a first-in-class bispecific immunotherapy agent that targets both the PD-L1 and 4-1BB pathways, leading to enhanced T-cell proliferation and antitumor immune response. It has demonstrated promising preclinical and early clinical activity, with manageable safety, especially in patients resistant to prior PD-(L)1 immunotherapy.

CANCER DISCOVERY (2022)

Add to Collection
Correction Biochemistry & Molecular Biology

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (vol 175, pg 313, 2018)

Miguel F. Sanmamed et al.

CELL (2019)

Add to Collection
Article Oncology

Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343

Marlon J. Hinner et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Review Hematology

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Cariad Chester et al.

BLOOD (2018)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.